The COVID-19 pandemic has generated an unprecedented amount of novel and repurposed vaccines and therapeutics that have been rapidly developed and implemented into clinical use. Unfortunately, pregnant persons have been excluded from most phase III clinical studies; therefore, our understanding regarding their safety for use in this population stems from understanding of theoretic risks and observational data. In this review, the authors discuss pregnancy-specific considerations for COVID-19 therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584862 | PMC |
| http://dx.doi.org/10.1016/j.ogc.2022.10.018 | DOI Listing |
Publication Analysis
Top Keywords
covid-19 therapeutics
8
therapeutics considerations
4
considerations pregnancy
4
pregnancy covid-19
4
covid-19 pandemic
4
pandemic generated
4
generated unprecedented
4
unprecedented amount
4
amount novel
4
novel repurposed
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!